ADC Therapeutics SA (ADCT) is a Great Momentum Stock: Should You Buy?

Zacks flags ADC Therapeutics (ADCT) as a high-momentum idea with a Momentum Style Score of A and a Zacks Rank #2 (Buy), citing strong recent price performance—shares up 28.6% over the past week, 6.8% over the month, 23.7% over the quarter and 123.8% over the past year—outperforming its Zacks Medical — Biomedical & Genetics peer group and the S&P 500; 20-day average volume is about 1.63 million shares. The momentum rating is underpinned by positive earnings-estimate revisions (two upward full-year revisions in the past 60 days that lifted the consensus from -$1.68 to -$1.47, plus one upward revision for next fiscal year), which together with price momentum support Zacks’ favorable near-term outlook. For institutional investors, the combination of accelerating price action and improving analyst estimates suggests potential near-term upside, although further fundamental catalysts should be monitored.

Analysis

Zacks highlights ADC Therapeutics (ADCT) as a high-momentum candidate, assigning a Momentum Style Score of A and a Zacks Rank #2 (Buy). Shares have risen 28.57% over the past week, 6.82% over the past month, 23.68% over the quarter and 123.81% over the past year, materially outperforming the Zacks Medical - Biomedical & Genetics industry (flat weekly, 1.95% monthly) and the S&P 500 (4% quarter, 14.09% year), while 20-day average volume is about 1,634,451 shares, signaling meaningful liquidity behind the move.

Momentum is supported by recent analyst estimate activity: two upward full-year revisions in the past 60 days lifted the consensus loss from -$1.68 to -$1.47 and one upward revision for the next fiscal year with no downward moves reported. Zacks notes that the combination of Rank #2 and an A/B Style Score has historically correlated with outperformance over the subsequent one-month period, implying potential near-term upside if the trend and revisions continue.

Principal risks are momentum reversal and the absence of positive EPS—estimates remain negative—so the stock remains sensitive to shifts in sentiment or news flow; the article provides no valuation context or specific upcoming catalysts beyond estimate revisions. Investors should therefore view ADCT as a tactical, momentum-driven opportunity and monitor volume sustainability, further estimate revisions, and any fundamental updates closely.

Key Decisions for Investors

• Consider a modest, tactical long position to capture near-term momentum given the A Momentum Score and recent outperformance, but size exposure conservatively and employ disciplined stop-loss or trailing-stop rules
• Monitor earnings-estimate revisions and consensus changes closely—if upward revisions persist consider adding, if revisions stall or reverse trim exposure
• Use 20-day average volume and intraday liquidity as confirmation: sustained above-average volume (~1.63M) supports the rally while declining volume would be a red flag
• Avoid treating this as a fundamental recovery while EPS remains negative; consider hedging or limiting allocation until clearer fundamental catalysts or positive cash-flow signals emerge